• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Aeterna Zentaris appoints Richard Sachse chief scientific officer

Aeterna Zentaris appoints Richard Sachse chief scientific officer

January 3, 2014
CenterWatch Staff

Aeterna Zentaris, a specialty biopharmaceutical company, has appointed Richard Sachse, M.D., Ph.D., senior vice president, chief scientific officer. Before joining Aeterna Zentaris, Sachse was vice president, head of Global Translational Medicine at Boehringer Ingelheim.

“Sachse will be responsible for all areas of our global R&D activities, while also working on the corporate Operating Committee. In developing his industry career, Sachse has held  increasingly responsible positions with several pharmaceutical companies, including Bayer, Schwarz Pharma, UCB and Boehringer Ingelheim, overseeing major drug development programs in oncology and endocrinology," said David Dodd, president and CEO of Aeterna Zentaris.

From 1996 to 2000, Sachse was International Project Leader at the Bayer Institute for Clinical Pharmacology, and Principal Investigator at the Bayer Clinical Pharmacology Unit, implementing innovative exploratory development tools, including biomarkers to demonstrate early proof-of-concept. From 2001 to 2006, Sachse held management positions within early and late phase clinical development programs, including responsibilities for completed phase III programs leading to successful NDA/MAA submissions. In 2007, after a merger, he became senior director, head of Experimental Medicine, at UCB in Belgium, where he managed the implementation of novel biomarkers in clinical development to provide data supporting identification of  appropriate target indication and target population. In 2010, Sachse became vice president, head of Global Translational Medicine at Boehringer Ingelheim.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing